BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12161350)

  • 1. Strategies other than dose-intensification should be pursued in elderly patients with untreated acute myeloblastic leukemia.
    Haematologica; 2002 Aug; 87(8):786. PubMed ID: 12161350
    [No Abstract]   [Full Text] [Related]  

  • 2. [The therapy of acute myeloid leukemia in patients of advanced age].
    Kern W; Schoch C; Fonatsch C; Heinecke A; Wörmann B; Büchner T; Hiddemann W
    Dtsch Med Wochenschr; 1999 Aug; 124(34-35):1005-14. PubMed ID: 10488328
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
    Doubek M; Palasek I; Brychtova Y; Buchtova I; Mayer J
    Neoplasma; 2005; 52(5):411-4. PubMed ID: 16151586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating novel treatment strategies into conventional therapy.
    Estey EH
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):4-7. PubMed ID: 19645129
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
    Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
    Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
    Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
    Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of intensive induction therapy in patients >or=70 years with acute myeloid leukemia.
    Gupta V; Xu W; Keng C; Alibhai SM; Brandwein J; Schimmer A; Schuh A; Yee K; Minden MD
    Leukemia; 2007 Jun; 21(6):1321-4. PubMed ID: 17344911
    [No Abstract]   [Full Text] [Related]  

  • 10. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
    Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "3+7" therapy for the treatment of acute myeloid leukemia. CON.
    Estey EH
    Clin Adv Hematol Oncol; 2005 Feb; 3(2):129-132, 141. PubMed ID: 16173152
    [No Abstract]   [Full Text] [Related]  

  • 13. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia.
    Buccisano F; Maurillo L; Del Poeta G; Gattei V; Amadori S; Venditti A
    Haematologica; 2006 Dec; 91(12 Suppl):ELT14; author reply ELT15. PubMed ID: 17194674
    [No Abstract]   [Full Text] [Related]  

  • 15. Survival of elderly patients with acute myeloid leukemia.
    Pulsoni A; Pagano L; Latagliata R; Casini M; Cerri R; Crugnola M; De Paoli L; Di Bona E; Invernizzi R; Marmont F; Petti MC; Rigolin G; Ronco F; Spadano A; Tosti ME; Visani G; Mele A; Mandelli F
    Haematologica; 2004 Mar; 89(3):296-302. PubMed ID: 15020267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia.
    Oriol A; Ribera JM; Brunet S; Esteve J; Bueno J; Llorente A
    Haematologica; 2003 Feb; 88(2):229-30. PubMed ID: 12604418
    [No Abstract]   [Full Text] [Related]  

  • 17. [Elderly patients with acute myeloid leukemia: characteristics in biology, patients, and treatment].
    Wedding U; Bokemeyer C; Meran JG; ; ;
    Med Klin (Munich); 2003 Apr; 98(4):193-207. PubMed ID: 12715143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
    Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
    Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.